


AMENDMENTS TO THE CLAIMS

1. (Original) A compound of the formula Y:



where;

R₁ is O, S;

R₂ is a nitrogen-containing heterocycle, wherein a nitrogen is located at the 2 position relative to the (thio)urea bond;

R₃ is H, C₁-C₃ alkyl,

R₄-R₇ are independently selected from H, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, haloC₁-C₆ alkyl, C₁-C₆ alkanoyl, haloC₁-C₆ alkanoyl, C₁-C₆ alkoxy, haloC₁-C₆ alkoxy, C₁-C₆ alkyloxy-C₁-C₆ alkyl, haloC₁-C₆ alkyloxyC₁-C₆ alkyl, hydroxyC₁-C₆ alkyl, aminoC₁-C₆ alkyl, carboxyC₁-C₆ alkyl, cyanoC₁-C₆ alkyl, amino, carboxy, carbamoyl, cyano, halo, hydroxy, keto;

X is -(CR₈R_{8'})_n-D-(CR₈R_{8'})_m;

D is a bond, -NR₉-, -O-, -S-, -S(=O)- or -S(=O)₂-;

n and m are independently 0, 1 or 2, provided that they are not both 0 when D is a bond;

R₈ and R_{8'} are independently H, C₁-C₃ alkyl, haloC₁-C₃alkyl, hydroxy, or R₈ and R_{8'} together with their adjacent C atom is -C(=O)-

R₉ is independently H, C₁-C₃ alkyl;

E is $-\text{CH}_2-$, $-\text{CHOH}-$, $-\text{C}(=\text{O})-$, $-\text{NR}_9-$, $-\text{O}-$, $-\text{S}-$, $-\text{S}(=\text{O})_2-$;

p and q are independently 0, 1 or 2, where $p+q \leq 2$;


R_{10} is an optionally substituted, saturated or unsaturated 5-7 membered carbocyclic ring or an optionally substituted, saturated or unsaturated 5-7 membered heterocyclic ring containing 1 to 3 hetero atoms selected from O, N and S;

R_{11} is independently H, $\text{C}_1\text{-C}_3$ alkyl, halo $\text{C}_1\text{-C}_3$ alkyl, hydroxy

with the proviso that $-(\text{CHR}_{11})_p\text{-E-(CHR}_{11})_q\text{-R}_{10}$ is not unsubstituted phenoxy;

and pharmaceutically acceptable salts and prodrugs thereof.

2. **(Original)** A compound according to claim 1, wherein R_1 is O.
3. **(Original)** A compound according to claim 1, wherein R_2 is pyridyl, isoxazolyl, benzothiazolyl, pyrimidinyl, pyrazinyl or thiazolyl.
4. **(Original)** A compound according to claim 3, wherein R_2 is pyrid-2-yl, substituted at the 5 position with the $-(\text{CHR}_{11})_p\text{-E-CHR}_{11})_q\text{R}_{10}$ moiety.
5. **(Original)** A compound according to claim 1, wherein R_3 is H.
6. **(Original)** A compound according to claim 1, wherein the cyclopropyl moiety has



an enantiomeric excess of the conformation depicted in the partial formulae:

where X is as defined, Y is the bridge to the (substituted) phenyl ring depicted in formula I and Z is bond to the (thio)urea- R_2 -(CHR₁₁)_p-E-(CHR₁₁)_q-R₁₀ moiety depicted in formula I.

7. **(Original)** A compound according to claim 1 wherein the compound of formula I comprises an enantiomeric excess of the isomer showing negative optical activity.

8. **(Currently Amended)** A compound according to claim 1, wherein D is -O-.

9. **(Original)** A compound according to claim 8, wherein n is 0 and m is 1.

10. **(Original)** A compound according to claim 1, wherein R₄ is hydrogen, fluoro or hydroxy.

12. **(Original)** A compound according to claim 1, wherein R₅ is hydrogen, fluoro, C₁₋₃ alkylcarbonyl or C₁₋₃alkyloxy.

13. **(Original)** A compound according to claim 1, wherein R₆ is hydrogen, halo, C₁₋₃alkyloxy, C₁₋₃alkylcarbonyl, cyano or ethynyl.

14. **(Original)** A compound according to claim 13 wherein R₆ is hydrogen, methoxy or fluoro.

15. **(Original)** A compound according to claim 1 wherein R₇ is hydrogen, halo, C₁₋₃alkyloxy, or C₁₋₃alkylcarbonyl.

16. **(Original)** A compound according to claim 15, wherein R₇ is fluoro.

17. **(Original)** A compound according to claim 1, wherein R₅ and R₆ are H and R₄ and R₇ are fluoro.

18. **(Original)** A compound according to claim 17, wherein X is $-\text{OCH}_2$, R_1 is O, R_2 is pyrid-2-yl and R_3 is H.
19. **(Currently Amended)** A compound according to claim 1, wherein $-(\text{CHR}_{11})_p\text{-E-}$
| $(\text{CHR}_{11})_q$ is $-\text{O-}$ or $-\text{S-}$.
20. **(Original)** A compound according to claim 1, wherein $-(\text{CHR}_{11})_p\text{-E-}(\text{CHR}_{11})_q$ is $-\text{CHOH-}$.
21. **(Original)** A compound according to claim 1, wherein $-(\text{CHR}_{11})_p\text{-E-}(\text{CHR}_{11})_q$ is $-\text{O-methylene}$ or $-\text{O-ethylene}$.
22. **(Original)** A compound according to claim 21 wherein R_{10} is N-morpholino.
23. **(Original)** A compound according to claim 1, wherein R_{10} is optionally substituted cycloalkyl, cycloalkenyl, phenyl, pyridyl, isoxazolyl, furyl, pyrimidyl, pyrazinyl, thiazolyl, imidazolyl, indolyl, triazolyl, piperidinyl, piperazinyl, or morpholinyl.
24. **(Original)** A compound according to claim 23, wherein R_{10} is halophenyl or cyanophenyl.
25. **(Original)** A compound according to claim 24, wherein R_{10} is fluorophenyl or fluorocyanophenyl.
26. **(Original)** A compound according to claim 23, wherein R_{10} is pyrid-3-yl or pyrid-4-yl.
27. **(Original)** A compound according to claim 26, wherein R_{10} is cyano or fluoro substituted pyrid-3-yl or pyrid-4-yl.

28. **(Original)** A pharmaceutical composition comprising a compound as defined in any preceding claim and a pharmaceutically acceptable vehicle or diluent therefor.

29. **(Original)** A composition according to claim 28, further comprising 1 to 3 additional HIV antivirals.

30. **(Currently Amended)** ~~Use of a compound as defined in any of claims 1-27 in the manufacture of a medicament for the~~A method of treatment or prophylaxis or treatment of HIV-1 infections comprising administering to a patient infected with HIV-1 an effective amount of the compound as defined by claim 1.

31. **(Currently Amended)** ~~Use according to~~The method of claim 30, wherein the said HIV-1 infection is a drug escape mutant.

32. **(Currently Amended)** ~~Use according to~~The method of claim 31, wherein the said drug escape mutant comprises the K103I mutation.